Uncoupling of p97 ATPase activity has a dominant negative effect on protein extraction

Halley B. Rycenga1, Kelly B. Wolfe1, Elizabeth S. Yeh2 & David T. Long1

p97 is a highly abundant, homohexameric AAA+ ATPase that performs a variety of essential cellular functions. Characterized as a ubiquitin-selective chaperone, p97 recognizes proteins conjugated to K48-linked polyubiquitin chains and promotes their removal from chromatin and other molecular complexes. Changes in p97 expression or activity are associated with the development of cancer and several related neurodegenerative disorders. Although pathogenic p97 mutations cluster in and around p97’s ATPase domains, mutant proteins display normal or elevated ATPase activity. Here, we show that one of the most common p97 mutations (R155C) retains ATPase activity, but is functionally defective. p97-R155C can be recruited to ubiquitinated substrates on chromatin, but is unable to promote substrate removal. As a result, p97-R155C acts as a dominant negative, blocking protein extraction by a similar mechanism to that observed when p97’s ATPase activity is inhibited or inactivated. However, unlike ATPase-deficient proteins, p97-R155C consumes excess ATP, which can hinder high-energy processes. Together, our results shed new insight into how pathogenic mutations in p97 alter its cellular function, with implications for understanding the etiology and treatment of p97-associated diseases.

p97/Cdc48/VCP (valosin-containing protein) is a highly abundant molecular chaperone that performs a variety of essential functions throughout the cell1–3. p97 forms a homo-hexameric AAA+ ATPase that relies on ATP hydrolysis to remodel and disassemble protein complexes4. p97 is recruited to substrate proteins by different binding partners that interact with K48-linked polyubiquitin chains5,6. K48-linked chains act as the primary signal for p97 recruitment and protein remodeling, although mono-ubiquitin and branched or mixed ubiquitin linkages may play additional roles in regulating p97 activity7,8. p97 interacts with multiple components of the 26S proteasome and has been shown to facilitate proteasomal degradation of various proteins9–11. However, p97 substrates can also be de-ubiquitinated in the absence of degradation and potentially recycled for future use12,13.

In cells, p97 plays an essential role in maintaining protein homeostasis as part of the endoplasmic reticulum-associated degradation (ERAD) pathway14. Misfolded proteins that accumulate in the endoplasmic reticulum (ER) due to error or stress are recognized by chaperones and directed to ubiquitin ligases that catalyze formation of K48-linked polyubiquitin chains15. p97 then facilitates extraction of ubiquitinated proteins from ER or ERAD-associated complexes, followed by protein degradation in the cytoplasm16. p97 also plays an analogous role in the nucleus called ubiquitin-dependent extraction from chromatin (UDEC)17,18. Extraction and degradation of chromatin-bound proteins is used to regulate dynamic changes in chromatin structure and function during DNA replication, damage signaling, gene expression, and chromosomal segregation12,19–24.

Due to its central role in many fundamental cellular pathways, disruption of p97 function can lead to several forms of disease. p97 expression is frequently up-regulated in multiple cancers and correlates with poor prognosis in patients25,26. These observations suggested that many cancers rely on p97 to manage cellular stress associated with tumorigenesis and that targeting p97 could improve anti-cancer therapeutics27,28. A series of p97 inhibitors have been developed that target p97’s ATPase activity, including DBeQ29, ML24030, NMS-87331, and CB-508332. Although each drug is highly active in vitro, CB-5083 has shown the most promise for in vivo studies33 and use in clinical trials (NCT02223598 and NCT02243917).

Each p97 subunit contains two tandem ATPase domains (D1 and D2) that support inter-subunit interaction and ATP hydrolysis34,35. The D1 and D2 domains are flanked by an N-domain and flexible C-terminus that serve as binding sites for different p97 cofactors3–36. Although p97 is essential for cellular viability33,37,38, heterozygous

1Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, 29425, USA. 2Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. Correspondence and requests for materials should be addressed to D.T.L. (email: longdt@musc.edu)
missense mutations can lead to a collection of related neurodegenerative diseases characterized by multisystem proteinopathy, including frontotemporal dementia (FTD), inclusion body myopathy (IBM), and Paget's disease of bone (PD)39,40. p97 mutations may also contribute to the development of amyotrophic lateral sclerosis (ALS)41,42, a progressive neurodegenerative disease affecting the brain and spinal cord.

Pathogenic mutations of p97 are most commonly found within the N-domain43. The majority of these p97 mutations were shown to convey normal or elevated ATPase activity in vitro39,44, suggesting that many disease symptoms result from elevated or unregulated p97 activity39,45. One of the most frequently mutated sites in p97 is arginine 155 (R155), located within the N-domain46. Here, we show that a common R155 mutation, R155C, leaves p97’s ATPase activity intact, but functionally uncouples it from protein extraction. As a result, p97-R155C acts as a dominant negative, remaining bound to ubiquitinated substrates and consuming excess ATP. These results reconcile conflicting biochemical and cellular observations, providing new insight on the molecular consequences of p97 dysfunction.

Results
Disruption of p97’s ATPase activity prevents its release from chromatin-bound substrates. To investigate how p97’s ATPase activity affects its interaction with potential substrates, we analyzed recruitment of p97 to plasmids incubated in Xenopus egg extract. When plasmid substrates are added to extract, they are rapidly chromatinized due to an abundance of histones present in egg cytoplasm46,47. Chromatinization creates a scaffold for numerous dynamic protein interactions, including those that support chromatin remodeling and DNA compaction48. Extract was supplemented with buffer or the p97 inhibitor CB-5083 (p97i). CB-5083 is a highly selective, competitive inhibitor that targets p97’s D2 ATPase domain49. Undamaged plasmid DNA (pDNA) was incubated in extract, and then DNA-bound proteins were isolated by plasmid pull-down and visualized by Western blot. Extract treated with buffer showed little or no p97 accumulation on DNA, even after 180 minutes (Fig. 1A, lanes 2–5). However, in the presence of p97i, the level of DNA-bound p97 increased dramatically (Fig. 1A, lanes 6–9); p97 inhibition also led to an increase in DNA-bound ubiquitin (Fig. 1A, compare lanes 3–5 and 6–9), suggesting that removal of ubiquitinated proteins was defective50. Consistent with this inference, we saw that a known p97 substrate, Aurora-B49, was enriched on DNA in the presence of p97i (Fig. S1A). We then pre-treated extract with the de-ubiquitinase inhibitor Ubiquitin Vinyl Sulfone (UbVS), which leads to depletion of free ubiquitin12,50–52. Loss of ubiquitin prevented the accumulation of both ubiquitinated proteins and p97 on DNA (Fig. 1A, lanes 10–13). Similar results were obtained using the p97 inhibitor NMS-873 (Fig. S2A–C), an allosteric non-competitive inhibitor that also blocks p97’s ATPase activity31.

We then asked whether p97 accumulation was dependent on the formation of K48-linked polyubiquitin chains, which act as the primary signal for p97-dependent protein extraction51,54. Extract was supplemented with p97i and either wild-type ubiquitin (Ub) or mutant ubiquitin containing an arginine substitution at lysine 48 (Ub-K48R). Compared to reactions supplemented with Ub, Ub-K48R led to a severe reduction in both DNA-bound p97 and ubiquitin (Fig. 1D, compare lanes 3–6 and 7–10). Thus, inhibiting p97’s ATPase activity in extract leads to its accumulation on DNA through interaction with putative substrates modified with K48-linked polyubiquitin chains. Although not all ubiquitinated proteins bound to DNA are likely to be p97 substrates, our results indicate that accumulation of p97 on DNA occurs through its interaction with these proteins.

In yeast, ATP hydrolysis was shown to be essential for the release of Cdc48 from ubiquitinated substrates16. To test whether inhibiting p97’s ATPase activity also had an effect on the interaction between p97 and its substrates, we first incubated pDNA in extract containing p97i for 180 minutes. DNA was then isolated from extract by plasmid pull-down and suspended in buffer with or without ATP. Retention of p97 on bead-bound DNA was then visualized by Western blot over time. When incubated in the absence of ATP, the level of DNA-bound p97 decreased by ~70% within 180 minutes (Fig. 2A, lanes 4–7; Fig. 2C, blue trace). In the presence of ATP, p97 displacement occurred more quickly, decreasing by ~90% within 180 minutes (Fig. 2A, lanes 9–12; Fig. 2C, green trace). When p97i was included in the incubation buffer, the majority of p97 remained bound at 180 minutes with or without addition of ATP (Fig. 2B, lanes 4–7 and 9–12; Fig. 2C gold and red traces). Using the p97 inhibitor NMS-873, we also saw that inhibition reduced p97’s displacement from DNA in the absence of ATP (Fig. S2D,E). Taken together, these results indicate that loss of ATPase activity influences p97 accumulation in two ways; both by increasing the number of DNA-bound substrates that p97 can interact with and by preventing the release of p97 from those substrates.

Cellular localization of p97 is revealed by protein inhibition. Our in vitro results predict that loss of ATPase activity leads to increased accumulation of p97 on chromatin, due to sequestration by ubiquitinated substrates. Although the cellular localization of some p97 mutants has been investigated55,56, the specific role that ATPase activity plays in protein localization is not well defined. We hypothesized that p97 inhibition first leads to sequestration of the protein on existing ubiquitinated substrates, prior to substrate accumulation and widespread cellular dysfunction57,58. Thus, limited exposure to p97i could provide an indicator of normal p97 utilization within cells. To investigate how p97 inhibition influences its sub-cellular localization in cells subject to different levels of chromatin stress, we treated non-transformed MCF-10A breast epithelial cells and MCF-7 breast adenocarcinoma cells with p97i for 24 hours and then visualized p97 by immunofluorescence. Cells were each treated with a “low” dose of p97i (1 μM), as well as a higher dose (2 μM) that was sufficient to induce expression of CHOP, an apoptosis-associated stress response marker49 (Fig. S4A,B). For each treatment, the relative fraction of total p97 that was localized to the nucleus was quantified and normalized to that observed in untreated cells. At the low dose, p97 inhibition had opposite effects on the relative fraction of nuclear p97 in MCF-10A cells, which decreased by 20% (Fig. 3A,B), and MCF-7 cells, which increased by 24% (Fig. 3C,D). These observations support the idea that cancer cells exhibit increased nuclear stress that is alleviated by p97. At the high dose of p97i, the
nuclear fraction of p97 increased in MCF-10A cells relative to the low dose and remained elevated in MCF-7
cells, suggesting that induction of apoptosis causes both cell types to retain or re-localize p97 within the nucleus.

To further investigate how p97 is localized within cells, MCF-7 and MCF-10A cells were treated with a range
of p97i concentrations, fractionated to isolate different cellular compartments, and then visualized by Western
blot. In MCF-10A cells, lower doses of inhibitor led to an increase in cytoplasmic p97 and decreases in both
soluble nuclear and chromatin-bound fractions (Fig. 4A,C–E, gray trace). These trends reversed at higher doses,
coinciding with induction of CHOP (Fig. S4A). In MCF-7 cells, p97i led to a dose-dependent reduction in cyto-
plasmic p97, and increases in both the soluble nuclear and chromatin-bound fractions (Fig. 4B,C–E, cyan trace).
Taken together, both immunofluorescence (Fig. 3) and fractionation (Fig. 4) data indicate that MCF-10A and
MCF-7 cells utilize p97 in different ways, leading to distinct patterns of sub-cellular localization when the protein
is sequestered on ubiquitinated substrates.

The R155C mutation functionally uncouples ATPase activity from protein extraction. To test
how pathogenic mutations in p97 affect its interaction with chromatin-bound substrates, extract was supple-
mented with recombinant hexameric complexes consisting of wild-type p97 (p97-WT), an ATPase-dead mutant

![Figure 1](https://example.com/fig1.png)

Figure 1. Inhibition of p97 leads to substantial accumulation on chromatin-bound substrates. (A) pDNA
was incubated in extract supplemented with buffer, the p97 inhibitor CB-5083 (p97i), or p97i and the de-
ubiquitinase inhibitor UbVS. DNA-bound proteins were isolated by plasmid pull-down at various times and
visualized by Western blot with the indicated antibodies. (B,C) Relative quantitation of DNA-bound p97 (B)
and DNA-bound ubiquitin (C) from three biological replicates. Values are normalized to peak accumulation in
the + Buffer reaction and error bars represent ±/− one standard deviation. (D) pDNA was incubated in extract
supplemented with p97i and either wild-type ubiquitin (Ub) or K48R mutant ubiquitin (Ub-K48R). DNA-
bound proteins were isolated by plasmid pull-down at various times and visualized by Western blot with the
indicated antibodies. Full Western blot images are available in Fig. S1.
or p97 containing an R155C mutation (p97-R155C). R155C is one of the most frequently identified p97 mutations and retains ATPase activity in vitro (Fig. S6)44,61. pDNA was incubated in extract for the time indicated, and then DNA-bound proteins were isolated by plasmid pull-down and visualized by Western blot.

Compared to wild-type p97, both the D1D2 and R155C mutants showed an increase in the accumulation of DNA-bound p97 and ubiquitin (Fig. 5A, compare lanes 2–5 with 6–9 and 10–13). Similar defects have also been observed in mouse models carrying different p97-R155 mutations61–63. These results indicate that both the D1D2 and R155C p97 proteins have a dominant negative effect on substrate unloading similar to that observed in the presence of p97i (Fig. 1A, lanes 6–9).

Notably, the accumulation of DNA-bound ubiquitin peaked earlier in the presence of p97-R155C (Fig. 5A, lane 11), indicating a defect not observed in the presence of p97i or p97-D1D2. Accumulation of histone H3 on pDNA was also decreased in the presence of p97-R155C (Fig. 5A, compare lanes 2–5 with 6–9 and 10–13). Histone loading is not dependent on p97 (Fig. 1A), suggesting that nucleosome assembly was compromised by an indirect mechanism. We speculated that constitutive activity of p97-R155C’s ATPase domain may consume energy required for normal plasmid chromatinization in extract64. When the p97-R155C reaction was supplemented with excess ATP regenerating mix (containing ATP, phosphocreatine, and creatine phosphokinase), the early accumulation of DNA-bound ubiquitin was reduced and histone H3 levels increased (Fig. 5D, compare lanes 1–2 and 4–5). Additional ATP also produced a mild increase in histone H3 loading in p97-WT reactions, but had no effect on the early accumulation of ubiquitin or histone H3 in p97-D1D2 reactions (Fig. 5D, compare lanes 1–2 and 4–5). These results indicate that the R155C mutation creates a requirement for additional ATP that can disrupt high-energy consuming processes like chromatinization.

To determine whether the R155C mutation also affects p97’s interaction with DNA-bound substrates, we incubated pDNA in extract supplemented with p97-WT, p97-D1D2, or p97-R155C for 180 minutes. DNA was then isolated from extract by plasmid pull-down and further incubated in buffer with or without ATP. Consistent with Fig. 5A, p97 accumulation was highly elevated in the presence of p97-D1D2 and p97-R155C, but showed little or no accumulation with p97-WT (Fig. 6A-C, lane 3). When pDNA was further incubated in buffer with or without ATP, both p97-D1D2 and p97-R155C remained bound to DNA throughout the reaction (Fig. 6B,C, lanes 4–6 and 8–10). Thus, both mutant proteins were unable to utilize ATP to promote displacement from chromatin. Taken together, Figs 5 and 6 demonstrate that the R155C mutation functionally uncouples p97’s ATPase activity from its protein extraction function.
ATPase inactivation creates a dominant negative effect.

p97 is an essential protein chaperone whose functions are tightly regulated to maintain cellular homeostasis. Using Xenopus egg extracts, we found that inhibiting p97’s ATPase activity led to a dramatic increase in the accumulation of both p97 and ubiquitinated proteins on DNA (Fig. 1A, lanes 6–9). Accumulation of p97 was dependent on ubiquitin (Fig. 1A, lanes 10–13) and the formation of K48-linked polyubiquitin chains (Fig. 1D), arguing that it is recruited to DNA through interaction with DNA-bound substrates. Thus, in the context of this system, p97’s normal function is to prevent the accumulation of ubiquitinated proteins on DNA.

Interestingly, the increase in DNA-bound ubiquitin was relatively mild compared to that of p97 (Fig. 1B,C). Using a dilution experiment to monitor p97 binding affinity for its DNA-bound substrates, we saw that inhibition of p97’s ATPase activity led to an increase in the accumulation of both p97 and ubiquitinated proteins on DNA (Fig. 2A,B, lanes 4–7). In yeast, ATP hydrolysis was shown to be essential for the release of Cdc48 from ubiquitinated substrates, suggesting that an induced conformational change helps to disrupt the cofactor-ubiquitin interaction that targets p97 to its substrates. We showed previously that failure to extract a p97 substrate from chromatin can lead to the formation of highly extended polyubiquitin chains. Together, these data support a model where p97 inhibition stabilizes the binding of multiple p97 complexes to a single, extended ubiquitin chain. As a result, inactive p97 complexes likely shield the substrate from extraction, thereby contributing to a dominant negative effect.

**Discussion**

**ATPase inactivation creates a dominant negative effect.** p97 is an essential protein chaperone whose functions are tightly regulated to maintain cellular homeostasis. Using Xenopus egg extracts, we found that inhibiting p97’s ATPase activity led to a dramatic increase in the accumulation of both p97 and ubiquitinated proteins on DNA (Fig. 1A, lanes 6–9). Accumulation of p97 was dependent on ubiquitin (Fig. 1A, lanes 10–13) and the formation of K48-linked polyubiquitin chains (Fig. 1D), arguing that it is recruited to DNA through interaction with DNA-bound substrates. Thus, in the context of this system, p97’s normal function is to prevent the accumulation of ubiquitinated proteins on DNA.

Interestingly, the increase in DNA-bound ubiquitin was relatively mild compared to that of p97 (Fig. 1B,C). Using a dilution experiment to monitor p97 binding affinity for its DNA-bound substrates, we saw that inhibition of p97’s ATPase activity led to a dramatic increase in the accumulation of both p97 and ubiquitinated proteins on DNA (Fig. 2A,B, lanes 4–7). In yeast, ATP hydrolysis was shown to be essential for the release of Cdc48 from ubiquitinated substrates, suggesting that an induced conformational change helps to disrupt the cofactor-ubiquitin interaction that targets p97 to its substrates. We showed previously that failure to extract a p97 substrate from chromatin can lead to the formation of highly extended polyubiquitin chains. Together, these data support a model where p97 inhibition stabilizes the binding of multiple p97 complexes to a single, extended ubiquitin chain. As a result, inactive p97 complexes likely shield the substrate from extraction, thereby contributing to a dominant negative effect.

**Figure 3.** Cellular localization of p97. (A) MCF-10A cells were plated for 24 hours and then treated with buffer or the indicated concentrations of CB-5083 (p97i). 24 hours after treatment, cells were visualized by immunofluorescence, with representative images shown (A). (B) Quantitation of relative nuclear abundance of p97 in (A), normalized to the mean in buffer-treated cells. (C,D) MCF-7 cells were treated, visualized (C), and quantitated (D), as in (A,B). Doses above 1.0 μM CB-5083 show elevated levels of the ER-associated stress and apoptosis marker CHOP (Fig. S4C). For each condition, three biological replicates were performed and a total of ≥40 cells were counted. Box plots are drawn from the first to third quartile and the median value is marked by a horizontal line. Whiskers extend to the minimum and maximum values. *p < 0.05, **p < 0.005, ***p < 0.0005, not significant (ns) p > 0.05.
Localization and utilization of cellular p97. Using a combination of immunofluorescence and cellular fractionation, we compared the cellular distribution of p97 in MCF-10A and MCF-7 cells. When treated with p97i, each cell line showed distinct patterns of p97 localization (Figs 3 and 4). At lower doses, these patterns provide a snapshot of the location and relative abundance of p97 substrates that interact with and sequester inhibited p97. At higher doses, p97 localization is likely dictated by the onset of apoptotic signals (Fig. S4A,B) that promote chromatin decondensation and nuclear collapse. Compared to MCF-10A, MCF-7 cells showed a significant increase in nuclear and chromatin-bound p97 (Figs 3 and 4), suggesting that MCF-7 cells rely more heavily on p97 to manage chromosomal stress associated with rapid cell growth and proliferation. MCF-7 cells are also aneuploid (with the number of chromosomes found in each cell ranging from 60 to 140), which could increase the frequency of p97-associated chromatin extraction events generated during cell cycle progression and in response to stress. These results support the idea that p97 represents an attractive target for therapeutic intervention that could provide selectivity during anti-cancer treatments.

Figure 4. Fractionation reveals p97 accumulation in specific cellular compartments. (A) MCF-7 and (B) MCF-10A cells were each plated for 24 hours and then treated with increasing amounts of CB-5083 (p97i). 24 hours after treatment, cells were collected and fractionated into cytoplasmic, soluble nuclear, and chromatin-bound fractions. Proteins from each fraction were then visualized by Western blot with the indicated antibodies. Actin and Histone H3 serve as loading controls for the indicated fractions. Full Western blot images are available in Fig. S5. (C–E) Relative quantitation of p97 accumulation in (C) cytoplasmic, (D) soluble nuclear, and (E) chromatin-bound fractions from three biological replicates. Values are normalized to total p97 levels (Fig. S4) and error bars represent ± one standard deviation.

Connecting p97 defects with disease etiology. To investigate p97 mutations found in the clinic, we supplemented extract with one of the most common p97 mutants, R155C, and analyzed its effect on chromatin extraction. We found that p97-R155C had a dominant negative effect on the accumulation of DNA-bound ubiquitin and p97 (Fig. 5A, lanes 10–13), indicating a functional defect in chromatin extraction. These results are consistent with previous studies showing that some p97 mutations associated with neurodegenerative diseases also led to an accumulation of ubiquitinated proteins. We also observed similar defects when p97’s ATPase activity was inhibited with CB-5083 (Fig. 1A, lanes 6–9) or NMS-873 (Fig. S2, lanes 6–9), and when p97’s D1 and D2 ATPase domains were mutated (Fig. 5A, lanes 6–9). However, by uncoupling rather than disabling p97’s ATPase activity, the R155C mutation also created additional defects (Fig. 5A, lanes 10–13) that were relieved by the addition of excess ATP (Fig. 5D, lanes 7–8). As such, p97-R155C likely binds to ubiquitinated substrates and promotes excessive ATP hydrolysis in a futile attempt to extract the protein. In our system, these defects were observed in the presence of elevated p97 levels and affected what is likely the most ATP-dependent event - chromatinization. However, in cells, excess ATP consumption more likely leads to chronic issues that affect multiple cellular processes. In Drosophila, defects associated with several p97 mutations (R155H, R191Q, and A232E) were relieved by increasing ATP levels, suggesting that excess ATP consumption is a common factor in disease.
etiology. Together, the combination of defects observed with p97 mutations may explain why disease primarily affects high energy-consuming organs and tissues\(^43\), where the requirement for both p97 function and ATP are highest.

**Treatment of p97-associated disease.** Despite p97’s naturally high abundance in cells\(^70\), many cancers may become increasingly reliant on p97 function to manage elevated stress associated with tumorigenesis\(^69,71\). Indeed, targeting p97 has been shown to induce apoptosis in multiple cancer cell lines and solid tumor mouse models\(^27,32,33,72\). p97 inhibitors also show promise for treatment of multiple myeloma, either as a single agent or in combination with proteasomal inhibitors\(^72,73\). For neurodegenerative diseases associated with p97 mutation, inhibiting ATP hydrolysis could influence p97 activity in different ways. For example, in this report, we show that R155C uncouples ATP hydrolysis from chromatin extraction. Although p97 inhibition could relieve defects associated with excess ATP consumption, it may also exacerbate the dominant negative effects of ATPase inactivation. However, p97 inhibition was recently shown to suppress several mitochondrial defects associated with p97 mutations R155H and A232E, suggesting a balance can be reached that provides therapeutic value\(^74\). Collectively, our results clarify the consequences of one of the most common p97 mutations and describe how protein dysfunction may contribute to disease etiology. Understanding the role that p97 plays in enabling or preventing different diseases will provide a rationale for targeting specific mechanisms during treatment.

**Methods**

**DNA incubation in *Xenopus* egg extracts.** *Xenopus* egg extracts were prepared as described previously\(^75\). Plasmid DNA was incubated in nucleoplasmic extract (NPE) at a final concentration of 50 ng/μL at 21 °C. Plasmids used in this study do not contain DNA damage and are not replicated during the reaction due to the absence of licensing in a high-speed supernatant (HSS) extract\(^46\). Where indicated, reactions were supplemented with: 150 mM NMS-873 (ApexBio Technology), 500 mM CB-5083 (PharmaBlock Sciences), 150μM Ubiquitin
Vinyl Sulfone (Boston Biochem), 50 μM recombinant ubiquitin (Boston Biochem), or 40 ng/μL recombinant p97. All experiments were performed three or more times and representative results are shown. Experiments involving vertebrate animals (Xenopus laevis) were performed in accordance with all guidelines and regulations using an approved protocol administered by the Medical University of South Carolina Institutional Animal Care and Use Committee (IACUC).

**Plasmid pull-down.** Isolation of plasmids from extract was performed as described previously. Briefly, streptavidin-coupled magnetic beads (Dynabeads M-280, Invitrogen) were washed three times with Tris Buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA pH 8, 0.02% Tween-20). Biotinylated LacI was then added to beads (12 pmol of LacI per 6 μL beads) and rotated at 21 °C for 40 minutes. The beads were washed four times with Pull-Down Buffer (10 mM Hepes pH 7.7, 50 mM KCl, 2.5 mM MgCl2, 250 mM sucrose, 0.25 mg/ml BSA, 0.02% Tween-20) and then stored at 4 °C until use. At the indicated time points, reaction samples were added to LacI-coupled magnetic beads and rotated for 20 minutes at 4°C. Beads were then washed three times with 250 μL of Wash Buffer (10 mM HEPES pH 2.7, 50 mM KCl, 2.5 mM MgCl2, 0.25 mg/ml BSA, and 0.03% Tween 20), dried, and resuspended in 2× SDS Sample Buffer (100 mM Tris-HCl pH 6.8, 4% SDS, 0.2% bromophenol blue,
20% glycerol, and 200 mM β-mercaptoethanol). Plasmid-bound proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and visualized by Western blotting with the indicated antibodies.

For dilution experiments, plasmids were incubated in extract for 180 minutes, isolated by plasmid pull-down, washed three times with Lac I wash buffer, and then resuspended in 100 volumes of Egg Lysis Buffer (ELB: 10 mM HEPES-KOH pH 7.7, 2.5 mM MgCl2, 50 mM KCl, 250 mM sucrose, and 1 mM DTT) supplemented with 5 mM ATP and/or 500 mM CB-5083 as indicated. After dilution, reactions were incubated at 21 °C for the indicated time, dried, and resuspended in 2x SDS Sample Buffer for analysis by Western blot. The following antibodies were used in this study: p97 (#612182) from BD Biosciences, histone H3 (#PA5-16183) from Thermo Fisher, ubiquitin (#PA1-187) from Pierce Biotechnology, actin (ab1801) from Abcam, and Aurora-B (A300-431AT) from Bethyl Laboratories.

**Protein expression and purification.** Expression constructs for *Xenopus laevis* wild-type His6-p97 and the D1D2 ATPase-inactive mutant (E305Q and E578Q) were provided by Olaf Stemmann (University of Bayreuth)76. The R155C mutation was introduced by Quikchange site-directed mutagenesis (Agilent Technologies) using the following primers:

Forward 5′-GGTGACATTTTCCCTGTTACTGGAGGGATGAGAGCC-3′
Reverse 5′-GGCTCTCATCCCCATTCAAGTGACAGAAATGTCACC-3′

Recombinant proteins were purified as described previously76,77. Briefly, bacterially expressed proteins were bound to Ni-NTA-agarose (Life Technologies), eluted with Ni-TE Elution Buffer (1 mM MgCl2, 100 mM KCl, 150 mM sucrose, 5 mM HEPES-KOH pH 7.4, 250 mM imidazole, 1 mM DTT), dialyzed against ELB, and then snap frozen for storage at −80 °C.

**ATPase activity assay.** The ATPase activity of recombinant p97 was measured using the ADP-Glo® Luminescent Kinase Assay (Promega). 500 μg of recombinant p97 (WT, D1D2, or R155C) was incubated in 25 μL of ELB containing 0.1 mM ATP with or without 0.1 mM CB-5083 at 21 °C. At the indicated times, 5 μL from each reaction was mixed with 5 μL of ADP-Glo reagent, and then incubated at 21 °C for 40 minutes. 10 μL of the Kinase Detection reagent was added and samples were incubated at 21 °C for 60 minutes. Luminescence from the converted ATP was then measured using a FilterMax F5 Multi-mode microplate reader (Molecular Devices).

**Imaging by immunofluorescence.** MCF-7 and MCF-10A cells were seeded onto coverslips in 6-well (34.8 mm) plates at a density of 10,000 cells per well. Cells were allowed to adhere to coverslips for 24 hours and then treated with increasing doses of CB-5083 or a DMSO buffer control. 24 hours after drug treatment, cells were fixed for 10 minutes in 4% paraformaldehyde in PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4, and pH adjusted to 7.4). Cells were then washed three times with PBS, incubated 1 hour with blocking buffer (5% FBS, 1% BSA, 0.2% Triton X-100 in PBS), and then incubated overnight with blocking buffer containing 1:500 anti-VCP antibodies (Fisher BDB612182). Cells were washed three times in PBS, incubated 1 hour with PBS containing 1:500 Alexa Fluor-488 (Fisher A-21202) secondary antibody, washed twice with PBS, and then mounted on slides using Vectashield containing DAPI (Vector). Z-stacked images of nuclei were taken with a step size of 1 μm using an Olympus FV10i LV laser scanning confocal microscope. Images were analyzed using FIJI. Z-stacked images were used to create a maximum Z projection and the pixel intensity was quantified. The relative fraction of nuclear p97 was represented as the total nuclear pixel intensity (average intensity × total nuclear area) divided by the total cellular pixel intensity (average intensity × total cellular area) normalized to the mean in buffer-treated cells. For cell clusters, nuclear and total intensities were determined in aggregate and used to determine the average abundance of each cell in the group.

**Cellular fractionation.** MCF-7 and MCF-10A cells were obtained from ATCC and cultured according to their specifications. Two million cells were plated in 10 cm dishes for 24 hours, and then treated with fresh media containing the indicated concentration of CB-5083 or a DMSO buffer control. After 24 hours, treated cells were harvested with 0.5% trypsin-EDTA, washed with cold PBS and then fractionated using the Subcellular Protein Fractionation Kit (Thermo Scientific). Total samples of whole cell lysates were also prepared by resuspending pelleted cells in 2× SDS Sample Buffer. Proteins were resolved by SDS-PAGE and visualized by Western blotting with the indicated antibodies.

**References**

1. Meyer, H. & Weihl, C. C. The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis. *Journal of cell science* **127**, 3877–3883 (2014).
2. Franz, A., Ackermann, L. & Hoppe, T. Ring of Change: CDC48/p97 Drives Protein Dynamics at Chromatin. *Frontiers in genetics* **12**, 3877–3883 (2014).
3. Rabinovich, E., Kerem, A., Frohlich, K. U., Diamant, N. & Bar-Nun, S. AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-associated protein degradation. *Molecular and cellular biology* **22**, 626–634 (2002).
4. Wang, Q., Song, C. & Li, C. C. Hexamerization of p97-VCP is promoted by ATP binding to the D1 domain and required for ATPase and biological activities. *Biochem Biophys Res Commun* **300**, 253–260 (2003).
5. Buchberger, A., Schindelin, H. & Hanzelmann, P. Control of p97 function by cofactor binding. *FEBS letters* **589**, 2578–2589, (2015).
6. Hänzelmann, P. & Schindelin, H. The Interplay of Cofactor Interactions and Post-translational Modifications in the Regulation of ATPase p97. *Frontiers in Molecular Biosciences* **4**, (2017).
7. Yau, R. & Rape, M. The increasing complexity of the ubiquitin code. *Nature cell biology* **18**, 579–586 (2016).
8. Ndoa, A., Cohen, R. E. & Yao, T. Ubiquitin signals proteolysis-independent stripping of transcription factors. *Molecular cell* **53**, 893–903 (2014).
9. Pye, V. E. et al. Structural insights into the p97-Ufd1-Npl4 complex. Proceedings of the National Academy of Sciences 104, 467 (2007).
10. Locke, M., Toli, J. I. & Petroski, M. D. K11- and K48-Linked Ubiquitin Chains Interact with p97 during Endoplasmic Reticulum-Associated Degradation. The Biochemical journal 459, 205–216 (2014).
11. Mallette, F. A. & Richard, S. K48-linked ubiquitination and protein degradation regulate 53BP1 recruitment at DNA damage sites. Cell Research 22, 1221–1223 (2012).
12. Fullbright, G., Ryenga, H. B., Gruber, J. D. & Long, D. T. p97 Promotes a Conserved Mechanism of Helicase Unloading during DNA Cross-Link Repair. Molecular and cellular biology 36, 2983–2994 (2016).
13. Meyer, H., Bug, M. & Bremer, S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nature cell biology 14, 117–123 (2012).
14. Preston, G. M. & Brodsky, J. L. The evolving role of ubiquitin modification in endoplasmic reticulum-associated degradation. The Biochemical journal 474, 445–469 (2017).
15. Xiao, X. & Rapoport, T. A. Mechanistic insights into ER-associated protein degradation. Current opinion in cell biology 53, 22–28 (2018).
16. Bodnar, N. O. & Rapoport, T. A. Molecular mechanism of substrate processing by the Cdc48 ATPas complex. Cell 169, 722–735. e729 (2017).
17. Dantuma, N. P. & Hoppe, T. Growing sphere of influence: Cdc48/p97 orchestrates ubiquitin-dependent extraction from chromatin. Trends in cell biology 22, 483–491 (2012).
18. Dantuma, N. P., Acz, K. & Lujisterburg, M. S. Should I stay or should I go: VCP/p97-mediated chromatin extraction in the DNA damage response. Experimental Cell Research 329, 9–17 (2014).
19. Maric, M., Mukherjee, P., Tatham, M. H., Hay, R. & Libab, K. Ufd1-Npl4 Recruit Cdc48 for Disassembly of Ubiquitylated CMG Helicase at the End of Chromosome Replication. Cell Reports 18, 3033–3042.
20. Moreno, S. P., Bailey, R., Campion, N., Herron, S. & Gambus, A. Polyubiquitylation drives replosome disassembly at the termination of DNA replication. Science (New York, N.Y.) 346, 477–481 (2014).
21. Maric, M., Maculins, N., De Piccoli, G. & Labib, K. Cdc48 and a ubiquitin ligase drive disassembly of the CMG helicase at the end of DNA replication. Science (New York, N.Y.) 346, 1253596 (2014).
22. Puuimalainen, M. R. et al. Chromatin retention of DNA damage sensors DDB2 and XPC through loss of p97 segregase causes genotoxicity. Nat Commun 5, 3695 (2014).
23. Raman, M. et al. A Genome-wide Screen Identifies p97 as an Essential Regulator of DNA Damage-Dependent CDT1 Destruction. Molecular cell 44, 72–84 (2011).
24. Verma, R., Oania, R., Fang, R., Smith, G. T. & Deshaies, R. J. Cdc48/p97 Mediates UV-Dependent Turnover of RNA Pol II. Molecular cell 41, 82–92 (2011).
25. Chapman, E., Maksim, N., de la Cruz, F. & La Clair, J. J. Inhibitors of the AAA+ chaperone p97. Molecules (Basel, Switzerland) 20, 3027–3049 (2015).
26. Fessart, D., Marza, E., Taura, S., Delom, F. & Chevet, E. P97/CDC48: proteostasis control in tumour cell biology. Cancer letters 337, 26–34 (2013).
27. Anderson, D. J. et al. Targeting the AAA ATPas p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis. Cancer cell 28, 653–665 (2015).
28. Lan, B., Chai, S., Wang, P. & Wang, K. VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy. Current molecular medicine 17, 608–618 (2017).
29. Chou, T. F. et al. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proceedings of the National Academy of Sciences of the United States of America 108, 4834–4839 (2011).
30. Chou, T. F., Li, K., Frankowski, K. J., Schoen, F. J. et al. Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem 8, 297–312 (2013).
31. Magnaghi, P. et al. Covalent and allosteric inhibitors of the ATPasase VCP/p97 induce cancer cell death. Nature chemical biology 9, 548–556 (2013).
32. Zhou, H. J. et al. Discovery of a First-in-Class, Potent, Selective and Orally Bioavailable Inhibitor of the p97 AAA ATPas (CB-5083). Journal of medicinal chemistry (2015).
33. LeMoigne, R. et al. The p97 Inhibitor CB-5083 Is a Unique Disruptor of Protein Homeostasis in Models of Multiple Myeloma. Molecular cancer therapeutics 16, 2375–2386 (2017).
34. Xia, D., Tang, W. K. & Ye, Y. Structure and function of the AAA+ ATPas p97/Cdc48p. Gene 583, 64–77 (2016).
35. DeLaBarre, B. & Brunger, A. T. Complete structure of p97/valosin-containing protein reveals communication between nucleotide domains. Nature Structural Biology 10, 856 (2003).
36. Hantzenmam, P. & Schindelin, H. The structural and functional basis of the p97/valosin-containing protein (VCP)-interacting motif (VIM): mutually exclusive binding of cofactors to the N-terminal domain of p97. The Journal of biological chemistry 286, 38679–38690 (2011).
37. Kobayashi, T., Tanaka, K., Inoue, K. & Kakizuka, A. Functional ATPaspe activity of p97/valosin-containing protein (VCP) is required for the quality control of endoplasmic reticulum in neuronally differentiated mammalian PC12 cells. The Journal of biological chemistry 277, 47358–47363 (2002).
38. Song, C., Wang, Q. & Li, C. C. ATPaspe activity of p97- valosin-containing protein (VCP). D2 mediates the major enzyme activity, and D1 contributes to the heat-induced activity. The Journal of biological chemistry 278, 3648–3655 (2003).
39. Tang, W. K. & Xia, D. Mutations in the Human AAA(-)-Chaperone p97 and Related Diseases. Frontiers in Molecular Biosciences 3 (2016).
40. Watts, G. D. et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature genetics 36, 377–381 (2004).
41. Johnson, J. O. et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68, 857–864 (2010).
42. Koppers, M. et al. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiology of aging 33(307), e837–e813 (2012).
43. Nalbandian, A. et al. The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. Journal of molecular neuroscience: MN 45, 522–531 (2011).
44. Niwa, H. et al. The Role of the N-Domain in the ATPaspe Activity of the Mammalian AAA ATPas p97/VCP. The Journal of biological chemistry 287, 8561–8570 (2012).
45. Chang, Y. C. et al. Pathogenic VCP/TER94 alleles are dominant actives and contribute to neurodegeneration by altering cellular ATP level in a Drosophila IBMPPD model. PLoS genetics 7, e1001288 (2011).
46. Walter, J., Sun, L. & Newport, J. Regulated Chromosomal DNA Replication in the Absence of a Nucleus. Molecular cell 1, 519–529 (1998).
47. Newport, J. Nuclear reconstitution in vitro: Stages of assembly around protein-free DNA. Cell 48, 205–217 (1987).
48. Clapier, C. R. & Cairns, B. R. The biology of chromatin remodeling complexes. Annual review of biochemistry 78, 273–304 (2009).
49. Ramadan, K. et al. Cdc48/p97 promotes reformation of the nucleus by extracting the kinase Aurora B from chromatin. Nature 450, 1258–1262 (2007).
50. Wilkinson, K. D. et al. A specific inhibitor of the ubiquitin activating enzyme: synthesis and characterization of adenosyl-phospho-ubiquitin, a nonhydrolyzable ubiquitin adenylate analogue. Biochemistry 29, 7373–7380 (1990).
51. Borodovsky, A. et al. A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. The EMBO Journal 20, 5187–5196 (2001).
52. Dimova, N. V. et al. APC/C-mediated multiple monoubiquitylation provides an alternative degradation signal for cyclin B1. Nature cell biology 14, 168 (2012).
68. Seibert, K.

67. Comsa, S., Cimpean, A. M. & Raica, M. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research.

76. Heubes, S. & Stemmann, O. The AAA-ATPase p97-Ufd1-Npl4 is required for ERAD but not for spindle disassembly in Xenopus egg extracts.

75. Lebofsky, R., Takahashi, T. & Walter, J. C. In DNA Replication: Methods and Protocols (eds Sonya Vengrova & Jacob Z. Dalgaard)

66. Rondón-Lagos, M.

62. Custer, S. K., Neumann, M., Lu, H., Wright, A. C. & Taylor, J. P. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBM/MDM including degeneration in muscle, brain and bone. Hum Mol Genet 19, 1741–1755 (2010).

61. Arhzaouy, K.

59. Su, N. & Kilberg, M. S. C/EBP Homology Protein (CHOP) Interacts with Activating Transcription.

58. Parzych, K., et al. Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97. Cell death & disease 6, e2031 (2015).

57. Bastola, P., Neums, L., Schoenen, F. J. & Chien, J. VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically ovarian cancer cells in combination with Salubrinal. Molecular. Oncology 10, 1559–1574 (2016).

56. Erzurumlu, Y., et al. A unique IBM/MDM-related p97/VCP mutation with differential binding pattern and subcellular localization. The International Journal of Biochemistry & Cell Biology 45, 773–782 (2013).

55. Erzurumlu, Y. & Rapoport, T. A. Function of the p97-Ufd1-Npl4 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains. The Journal of cell biology 162, 71–84 (2003).

54. Finley, D. et al. Inhibition of proteolysis and cell cycle progression in a multiquabitination-deficient yeast mutant. Molecular and cellular biology 14, 5501–5509 (1994).

53. Ye, Y., Meyer, H. H. & Rapoport, T. A. Function of the p97-Ufd1-Npl4 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains. The Journal of cell biology 162, 71–84 (2003).

52. Yeo, Y., Meyer, H. H. & Rapoport, T. A. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature 414, 652 (2001).

51. Arhzaouy, K. et al. Heteromorphic p97/p97R155C complexes induce dominant negative changes in wild-type and autophagy 9-deficient Dictyostelium strains. PloS one 7, e46879 (2012).

50. Custer, S. K., Neumann, M., Lu, H., Wright, A. C. & Taylor, J. P. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBM/MDM including degeneration in muscle, brain and bone. Hum Mol Genet 19, 1741–1755 (2010).

49. Weihl, C. C., Miller, S. E., Hanson, P. I. & Pestronk, A. Transgenic expression of inclusion body myopathy associated mutant p97/ VCP causes weakness and ubiquitinated protein inclusions in mice. Hum Mol Genet 16, 919–928 (2007).

48. Almouzni, G. & Wolff, A. P. Nuclear assembly, structure, and function: the use of Xenopus in vitro systems. Exp Cell Res 205, 1–15 (1993).

47. Vaz, B., Halder, S. & Ramadan, K. Role of p97/VCP (Cdc48) in genome stability. Frontiers in genetics 4, 60 (2013).

46. Rondón-Lagos, M. et al. Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis. Molecular Cytogenetics 7, 8–8 (2014).

45. Comsa, S., Cimpean, A. M. & Raica, M. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. Anticancer Res 35, 3147–3154 (2015).

44. Seibert, K. et al. Clonal Variation of MCF-7 Breast Cancer Cells in vitro in Vivo in vitro and in Aethymic Nude Mice. Cancer research 43, 2223–2239 (1983).

43. Vekaria, P. H., Home, T., Wein, S., Schoenen, F. J. & Rao, R. Targeting p97 to Disrupt Protein Homeostasis in Cancer. Frontiers in oncology 6, 181 (2016).

42. Ye, Y., Tang, W. K., Zhang, T. & Xia, D. A Mighty “Protein Extractor” of the Cell: Structure and Function of the p97/CDC48 ATPase. Frontiers in Molecular Biosciences 4 (2017).

41. Xia, D. & Ye, Y. In Search of a Cure for Proteostasis-Addicted Cancer: A AAA Target Revealed. Cancer cell 28, 550–552 (2015).

40. Auner, H. W. et al. Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. Plos one 8, e74415 (2013).

39. Wang, Q. et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proceedings of the National Academy of Sciences of the United States of America 106, 2200–2205 (2009).

38. Zhang, T., Mishra, P., Hay, B. A., Chan, D. & Guo, M. Valosin-containing protein (VCP/p97) inhibitors relieve Mitofusin-dependent mitochondrial defects due to VCP disease mutants. eLife 6, e17834 (2017).

37. Lebofsky, R., Takahashi, T. & Walter, J. C. In DNA Replication: Methods and Protocols (eds Sonya Vengrova & Jacob Z. Dalgaard) 229–252 (Humana Press, 2009).

36. Heubes, S. & Steemann, O. The AAA-ATPase Cdc48/p97 is required for ERAD but not for spindle disassembly in Xenopus egg extracts. Journal of cell science 120, 1325–1329 (2007).

35. Heubes, S. The AAA-ATPase p97 in mitosis and fertilization (2007).

Acknowledgements
This work was supported by the National Institutes of Health: R35 GM119512 to DTL, R01 CA187305 to ESY, T32 CA193201 to KBW, and TL1 TR001451/UL1 TR001450 to HBR.

Author Contributions
D.T.L., H.B.R. and E.S.Y. designed experiments; H.B.R. and K.B.W. performed experiments; D.T.L., H.B.R. and E.S.Y. analyzed the data; and D.T.L. and H.B.R. prepared the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-46949-4.

Competing Interests: The authors declare no conflict of interest. Reagents and materials described in this manuscript are available upon request from the corresponding author, according to NIH guidelines.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019